TAAR1
ENSG00000146399
Target class
GPCR
Chromosome
6
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- TAAR1
- Gene name
- Trace amine associated receptor 1
- Gene symbol
- TAAR1
- Previous gene symbols
- TRAR1
- Protein name
- Trace amine-associated receptor 1 (TaR-1) (Trace amine receptor 1)
- TAR1
- TA1
- Gene biotype
- Protein coding
- Gene family
- Trace amine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 0
- Highest tissue expression
- 0.02
- Tissue specificity (Gini)
- 0.981
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:134864
- Protein interaction confidence
- 0.8055
- Protein interaction partners
- 2
- R-HSA-375280
- R-HSA-418555
- End position
- 132659182
- Start position
- 132643312
- Chromosome
- 6
- Strand
- Reverse
- Endomembrane system . Endoplasmic reticulum membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein . Note=Localizes mainly intracellularly (PubMed:11723224, PubMed:31399635, PubMed:36100653). Partially colocalizes with the endoplasmic reticulum
- also found at lower lever at the plasma membrane (PubMed:36100653). .
- PubMed 11723224
- PubMed 31399635
- PubMed 36100653
- PubMed 37935376
- PubMed 37935377
- PubMed 37963465
- PubMed 38168118
- Tissue specificity (tau)
- 1
- Expression inequality (Gini)
- 0.981481
Expression in transcripts per million
- Kidney - Medulla
- 0.02
- Adipose - Subcutaneous
- 0
- Brain - Amygdala
- 0
- Brain - Cortex
- 0
- Esophagus - Mucosa
- 0
Expression in transcripts per million
- Kidney - Medulla0.02
- Adipose - Subcutaneous0
- Brain - Amygdala0
- Brain - Cortex0
- Esophagus - Mucosa0
- Adipose - Visceral (Omentum)0
- Lung0
- Liver0
- Brain - Anterior cingulate cortex (BA24)0
- Brain - Spinal cord (cervical c-1)0
- Brain - Frontal Cortex (BA9)0
- Brain - Cerebellar Hemisphere0
- Esophagus - Gastroesophageal Junction0
- Cells - EBV-transformed lymphocytes0
- Fallopian Tube0
- Bladder0
- Nerve - Tibial0
- Colon - Transverse0
- Brain - Nucleus accumbens (basal ganglia)0
- Stomach0
- Cervix - Ectocervix0
- Prostate0
- Brain - Putamen (basal ganglia)0
- Heart - Left Ventricle0
- Colon - Sigmoid0
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007189
- GO:0007193
- GO:0007200
- GO:0005886
- GO:0012505
- GO:0001594
- GO:0004930
- GO:0005515
Related records
Trials (28)
- A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
- A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
- A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
- A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
- A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
- A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
- A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
- A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
- A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
- A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
- A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
- A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
- A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
- A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
- A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
- A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Drugs (1)
- Ulotaront Trace amine-associated receptor 1 agonist